Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases

Study Overview
=================
Brief Summary
-----------------
Acquired inflammatory or infectious cardiac diseases, in pediatrics, include Kawasaki disease, myocarditis, and Covid-19-related Pediatric Multisystemic Inflammatory Syndrome (PIMS). These 3 inflammatory cardiac diseases have clinical, biological, and echographic similarities and differences. Nevertheless their modalities of monitoring, management and evolution are different. The investigators wish to retrospectively analyze biological and echocardiographic data of Kawasaki disease, myocarditis, PIMS patients managed at Nancy Children Hospital from January 1, 2017 to June 31, 2023. The primary objective of this study is to identify, for these 3 pathologies, the prognostic factors of initiation of inotropic support. The secondary objective is to identify the prognostic factors of degradation of ventricular function.

Official Title
-----------------
Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases (Including Pediatric Inflammatory Multisystemic Syndromes Related to Covid 19, Kawasaki Disease and Myocarditis)

Conditions
-----------------
Myocarditis, Pediatric Inflammatory Multisystem Syndrome, Kawasaki Disease

Intervention / Treatment
-----------------
* Other: study of biological samples and echocardiographic data and link with need of hemodynamic support


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnostic of PIMS, myocarditis or kawasaki disease patients age < 18 years Exclusion Criteria: uncertain diagnosis other complex heart disease management out of Nancy University children hospital center

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| MYOCARDITIS<br>No intervention Study of available clinical, biological, and echocardiographic data | Other: study of biological samples and echocardiographic data and link with need of hemodynamic support<br>* observational study : there is no intervention<br>|
| KAWASAKI<br>No intervention Study of available clinical, biological, and echocardiographic data | Other: study of biological samples and echocardiographic data and link with need of hemodynamic support<br>* observational study : there is no intervention<br>|
| PIMS<br>No intervention Study of available clinical, biological, and echocardiographic data | Other: study of biological samples and echocardiographic data and link with need of hemodynamic support<br>* observational study : there is no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| need of hemodynamic support | The need for haemodynamic support is defined dichotomously: yes or no. The investigators wish to identify the predictive factors of need for haemodynamic support among the following variables: groups (PIMS, KAWASAKI, MYOCARDITIS), cardiac biomarkers (troponin and NT-pro-BNP at admission (in ng/ml)) and echocardiographic criterias (Left Ventricular Ejection fraction, global and regional longitudinal strain at admission (in %)). | up to 20 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| deterioration of Left Ventricular Ejection fraction | Left Ventricular Ejection fraction degradation is defined as an Left Ventricular Ejection fraction below the value of the first quartile of Left Ventricular Ejection fraction of all patients taken into account (Left Ventricular Ejection fraction as a percentage). The investigators wish to identify the predictive factors of Left Ventricular Ejection fraction degradation among the following variables: groups (PIMS, KAWASAKI, MYOCARDITIS), cardiac biomarkers (troponin and NT-pro-BNP at admission (in ng/ml)) and echocardiographic criterias (Left Ventricular Ejection fraction , global and regional longitudinal strain at admission (in %)). | up to 20 days |